Search

Search Constraints

You searched for: Author/Creator Wallet, Jennifer

Search Results

1. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. (February 2020)

3. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. (August 2018)

4. Erratum to "Outcomes of the use of different vulvar flaps for reconstruction during surgery for vulvar cancer" [Eur J Surg Oncol 45 9 (2019) 1625-1631]. Issue 10 (October 2020)

5. Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. Issue 1 (December 2016)

6. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Issue 4 (22nd October 2019)

8. REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis. Issue 12 (10th March 2017)

9. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 12 (December 2016)

10. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. Issue 1 (December 2016)